

Bioresorbable magnesium implants from Syntellix approved in Colombia

Australia grants approval for coated MAGNEZIX® CS^c bone screw

Hanover, June 10, 2021. The Colombian Ministry of Health Minsalud has approved the use of bioresorbable magnesium implants for the surgical stabilization of bones. This enables Syntellix AG to launch its successful MAGNEZIX® CS ("Compression Screws") product family in Latin America's fourth largest economy. After overcoming the Corona crisis, its medical technology market will grow at an above-average rate to 1.6 billion US dollars by 2024, according to a forecast by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany. Colombia is the 69th country in which Syntellix has achieved regulatory approval, following recent additions of Brazil and the Philippines. Good news also from Australia, where the health authority is extending the approval already in place since 2016 to include the ceramized MAGNEZIX® CS^c 4.8, the largest dimension in the CS range to date.

In orthopedics and trauma surgery, compression screws made of the patent-protected alloy MAGNEZIX® are used to fix small and medium-sized bones after an accident or to correct a malposition. The highlight: The implant is as stable as comparable products made of titanium and "transforms" into bone in due course. This eliminates the need for surgery to remove common metal implants, which is often necessary, and thus prevents the risk of infection, for example from hospital germs.

The product will be marketed in Colombia by a local distribution partner. The country is home to over 50 million people, and top hospitals enjoy an excellent reputation beyond the country's borders. "The Colombian market is particularly exciting," comments Syntellix Chief Medical Officer Prof. Dr. Martin Kirschner, "because healthcare providers are very progress-oriented and patients place a particularly high value on innovative and state-of-the-art products."

About Syntellix:

Syntellix AG, a multi-award-winning global pioneer in Biomedical Engineering, Materials & Life Science, is the worldwide market leader in the field of bioabsorbable magnesium-based metallic orthopedic implants. Currently, about 40 medical-scientific publications prove the safety, efficacy and reliability of the MAGNEZIX® implants developed by Syntellix, which are described as "advantageous" or even "clinically superior" to conventional titanium implants for numerous clinical applications.

Syntellix AG
Aegidientorplatz 2a
30159 Hannover
Deutschland

T +49 511 270 413 50
F +49 511 270 413 79

info@syntellix.com
www.syntellix.com

Vorstand
Prof. Dr. rer. pol.
Utz Claassen
Vorsitzender/CEO &
Chief Disruption Officer
Dr. rer. pol. oec.
Amir S. Ghoreishi
Chief Financial Officer
Prof. Dr. med.
Martin Kirschner
Chief Medical Officer

Aufsichtsratsvorsitz
Annette Claassen

Sitz der Gesellschaft
Hannover
Amtsgericht Hannover
HRB 202618

Ansprechpartner
Syntellix AG:

Michael Blum
presse@syntellix.com